Detalhe da pesquisa
1.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLoS Med
; 19(1): e1003865, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015777
2.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
PLoS Med
; 18(10): e1003813, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714820
3.
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
PLoS Negl Trop Dis
; 18(4): e0011500, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603720
4.
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Vaccines (Basel)
; 12(2)2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400193
5.
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
EBioMedicine
; 91: 104562, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099841
6.
Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.
Int J Infect Dis
; 118: 224-229, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227869
7.
Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study.
Ther Clin Risk Manag
; 17: 1187-1198, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34815671